Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights
- 1 April 2012
- journal article
- review article
- Published by Elsevier BV in Kidney International
- Vol. 81 (8), 727-732
- https://doi.org/10.1038/ki.2011.500
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodiesKidney International, 2011
- Pure Red Cell Aplasia Induced Only by Intravenous Administration of Recombinant Human ErythropoietinActa Haematologica, 2011
- Quality of Original and Biosimilar Epoetin ProductsPharmaceutical Research, 2010
- On the Role of Aggregates in the Immunogenicity of Recombinant Human Interferon Beta in Patients with Multiple SclerosisJournal of Interferon & Cytokine Research, 2010
- Precipitation of a Monoclonal Antibody by Soluble TungstenJournal of Pharmaceutical Sciences, 2009
- Epoetin‐associated pure red cell aplasia: past, present, and future considerationsTransfusion, 2008
- Pure Red Cell Aplasia Induced by Erythropoiesis-Stimulating AgentsClinical Journal of the American Society of Nephrology, 2008
- Pure Red-Cell Aplasia and Epoetin TherapyThe New England Journal of Medicine, 2004
- Treatment of erythropoietin-induced pure red cell aplasia: a retrospective studyThe Lancet, 2004
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinThe New England Journal of Medicine, 2002